Bacampicillin in acute maxillary sinusitis: concentration in sinus secretion and clinical effect. A randomized, double-blind study of two dosage regimens.
The clinical effect and the penetration of ampicillin into sinus secretion after oral administration of bacampicillin was studied in 47 patients with acute maxillary sinusitis allocated at random in treatment with 400 mg bacampicillin 3 times or 1200 mg twice daily. The overall clinical effect was similar and was assessed as "good" in 23/25 patients treated with 400 mg doses and in 19/22 treated with 1200 mg. Adverse reactions were reported by 4 patients. The concentrations of ampicillin obtained in sinus secretion were proportional to the dose given. The highest values after 400 mg bacampicillin were approximately 0.6 mg/l and after 1200 mg about 2 mg/l. Both dosages are applicable to treatment of acute maxillary sinusitis.
D000208:Acute Disease; D000328:Adult; D000367:Age Factors; D000667:Ampicillin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008443:Maxillary Sinus / Q000378:metabolism; D008875:Middle Aged; D011859:Radiography; D012737:Sex Factors; D012852:Sinusitis / Q000000981:diagnostic imaging / Q000188:drug therapy*
D000667:Ampicillin; C011674:bacampicillin